Sun Pharmaceutical Industries Ltd

💊 Sun Pharma to Acquire Organon in $11.75B Deal, Expanding Global Footprint 🌍

- Acquisition of Organon & Co. for $14.00 per share in cash, with equity value of $3.99B and enterprise value of $11.75B.

- Projected synergies exceeding $350M within 2–4 years.

- Combined entity expected to generate nearly double EBITDA and cash flows.

- Organon adds biosimilars business with ~$700M revenue and portfolio of 50+ established brands, including 15 with $100M+ revenue each.

- Post-merger, Innovative Medicines will represent 27% of combined revenue, while Established Brands/Branded Generics will account for 51%.

- Combined operations span 150+ countries, with significant presence in US, EU, China, and other key markets.

- Organon brings strengths in Women’s Health (ranked 2 in contraceptives, 3 in fertility globally) and biosimilars (ranked 7 globally).